Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Key Terms
contract development and manufacturing organization (cdmo)technical
A contract development and manufacturing organization (CDMO) is a company that develops and produces drugs, vaccines or other medical products for other firms, handling steps from formulation and testing to large-scale manufacturing and quality control. Investors care because CDMOs function like outsourced specialized factories and development partners: their revenue grows when many clients need production capacity or development expertise, so their performance signals broader industry demand and is tied to regulatory approvals and client programs.
oligonucleotidesmedical
Short strands of DNA or RNA designed to bind specific genetic sequences, oligonucleotides act like targeted messages that can turn genes on or off, block harmful proteins, or help detect disease. For investors, they matter because they represent a class of therapeutic and diagnostic products with potential for highly specific treatments, large market value, and distinct development, manufacturing and regulatory risks that can drive big gains or setbacks depending on clinical success and approval.
microbial fermentationmedical
Microbial fermentation is a process where tiny living organisms such as bacteria, yeast, or fungi convert raw ingredients into useful products—like turning sugars into enzymes, medicines, proteins, or chemicals—using controlled tanks instead of chemical factories. For investors it matters because this method can lower production costs, scale supply, and enable new products; think of it like switching from handcrafting to an automated bakery that can make more loaves faster and cheaper while creating goods that didn’t exist before.
highly potent apismedical
Highly potent APIs are the concentrated active drug ingredients that produce a medicine’s effects at very small doses, like a pinch of a strong spice compared with a cup of a mild one. They matter to investors because making and handling them requires special facilities, safety controls and regulatory oversight, which raises development costs and barriers to entry but can also command higher margins and create supply, liability and approval risks that affect company value.
cell line developmentmedical
Cell line development is the laboratory process of creating a stable, reproducible population of cells that can be used to make biological products, run tests, or support research. For investors, it matters because the chosen cell line is like picking a factory and workforce: it determines how reliably and cheaply a drug or vaccine can be produced, affects quality control and regulatory approval risk, and therefore influences timelines, costs and potential returns.
SANTA CLARA, Calif.--(BUSINESS WIRE)--
Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States.
Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing solutions.
Agilent Advanced Therapeutics’ CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform provides customers streamlined access to end-to-end development and manufacturing services through a single partner — from discovery and process development through clinical- and commercial-scale manufacturing.
“The Agilent Advanced Therapeutics solution strengthens our ability to support our customers and reinforces our long-term commitment to growth, investment, and leadership in this space,” said Agilent President and CEO, Padraig McDonnell. “For our customers, this means a more integrated experience, deeper technical partnership and a trusted team that understands what it takes to bring life-changing therapies to patients.”
Simon May, president of Agilent’s Life Sciences and Diagnostics Markets Group, added: “This launch reflects the combined excellence of our teams and our commitment to advancing the next generation of therapies. We are excited to bring our unified Agilent Advanced Therapeutics capabilities to partners around the world.”
Additional details regarding Agilent Advanced Therapeutics are available on our website.
About Agilent Technologies
Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
